Loading, Please Wait...

CST: 17/11/2019 04:35:34   

Generex Biotechnology Announces that Excellagen® Inventor, Dr. Lois Chandler will Present Clinical Data on Rapid Healing of Diabetic Foot Ulcers at The Symposium on Advanced Wound Care (SAWC) Fall Meeting

37 Days ago

  • Special poster reception on October 13, 2019, at Caesars Palace, Las Vegas, the official site of the SAWC Meeting
  • Clinical data demonstrate accelerated healing of diabetic neuropathic foot ulcers with Excellagen wound conforming gel matrix

MIRAMAR, Fla., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased and proud to announce that Dr. Lois Chandler, inventor of Excellagen and an advisor to our subsidiary, Olaregen Therapeutix, will be presenting the poster entitled “Wound Conforming Matrix Containing Purified Homogenate of Dermal Collagen Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers: Subset Analysis of Randomized Controlled Trial” during a special poster reception on October 13, 2019, at Caesars Palace, Las Vegas, the official site of the SAWC Meeting. The poster will present clinical data demonstrating significant acceleration of healing rates in patients with chronic diabetic neuropathic foot ulcers following a single application of Olaregen’s Excellagen (2.6% formulated fibrillar collagen) and increased wound closure incidences as compared with Standard of Care (SOC).

Dr. Chandler’s co-authors on the poster include Oscar Alvarez, PhD of Rutgers University, Peter Blume, DPM, FACFAS of Yale University, Paul Kim, DPM of the University of Texas, Robert Kirsner, MD, PhD  of the University of Miami, John Lantis, MD of Mount Sinai Hospital – NY, and William Marston, MD  of the University of North Carolina.

“We are excited for Dr. Chandler to present the clinical trial data that demonstrates statistically significant healing rates in diabetic foot ulcers with just a single application of Excellagen.” said Anthony J. Dolisi, President and Chief Executive Officer of Olaregen and Chief Commercial Officer for Generex. “We are happy to report that we continue to see these results replicated in clinical practice as we launch Excellagen in three sizes including 0.5, 0.8, and now 3.0 cc pre-filled syringes.”

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products. 

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

About Olaregen Therapeutix
Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. Generex aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides. Olaregen's initial focus will be in advanced wound care including diabetic foot ulcers (DFU), venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline. Generex's mission is to become a significant force in regenerative medicine and advance the science of healing.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato
646-599-6222

Todd Falls
1-800-391-6755 Extension 222
investor@generex.com 

Is your business listed correctly on America’s largest city directory network of 1,000 portals?